Investor presentation
Logotype for Journey Medical Corp

Journey Medical (DERM) Investor presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for Journey Medical Corp

Investor presentation summary

12 Nov, 2026

Financial position and portfolio

  • 2025 net product revenue $61M and adjusted EBITDA $2.9M; cash $25.6M as of June 30, 2026.

  • Market cap $190M, shares outstanding 28.2M and average volume 185K, with market data as of Oct. 1, 2026.

  • Five core dermatology brands span rosacea, acne and hyperhidrosis; portfolio includes Emrosi, Qbrexza, Amzeeq, Accutane and Fzilxi.

  • Prescription dermatology markets targeted total ~$5.8B; products acquired since 2021 contribute over 90% of net revenue.

Emrosi clinical profile

  • FDA-approved in November 2024 and launched in the U.S. in April 2025; once-daily 40 mg capsule combines 10 mg immediate-release and 30 mg extended-release minocycline.

  • Two Phase 3 trials showed statistically significant superiority to Oracea and placebo on IGA treatment success and inflammatory lesion reduction at week 16.

  • Relative to Oracea, IGA treatment success was 61% greater and inflammatory lesion reduction 28% greater; treatment success was 122% and lesion reduction 68% greater than placebo.

  • Efficacy was observed as early as week 2 versus placebo; key treatment-related adverse events were low and most were mild or moderate, with a safety profile described as similar to placebo.

  • Three U.S. Orange Book-listed patents were issued, with expected market exclusivity to 2039; Phase 3 data appeared in JAMA Dermatology in March 2025.

Emrosi commercial progress and opportunity

  • Through July 2026, more than 130,000 prescriptions had been filled and over 4,500 unique providers had prescribed Emrosi.

  • Payer access covered more than 85% of U.S. commercial lives; quarterly TRx rose from 7,394 in Q2 2025 to 35,882 in Q2 2026.

  • The sales force covers 87% of oral rosacea dermatology TRx in its territories; 94% of oral rosacea TRx were written in dermatology in 2025.

  • U.S. rosacea treatment sales were over $1.3B in 2025; Oracea had $252M in prescription sales, and U.S. Emrosi net sales potential was stated to exceed $200M.

  • Global net sales potential was stated at over $300M; potential international out-licensing is an additional opportunity.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Journey Medical